A phase 2 trial of bevacizumab in lung cancer, run by Kamya Sankar, now recruiting.
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases is a phase 2, interventional study registered as NCT05588388 by Kamya Sankar, with a registry enrolment figure of 39 participants, started 2024-08-11 and due to reach its primary completion in 2026-12-28. Interventions recorded: Bevacizumab. Conditions listed: Extensive-stage Small-cell Lung Cancer; Liver Metastases. Primary outcome: 6- month Progression Free Survival (PFS) rate. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group staging system), and radiographic confirmation of LM at diagnosis". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.